Linked Life Data

14514738

Source:http://linkedlifedata.com/resource/pubmed/id/14514738

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14514738rdf:typepubmed:Citationlld:pubmed
pubmed-article:14514738lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C0015576lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C2717879lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C1567741lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C1567742lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C0175860lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C0015179lld:lifeskim
pubmed-article:14514738lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:14514738pubmed:issue10lld:pubmed
pubmed-article:14514738pubmed:dateCreated2003-9-29lld:pubmed
pubmed-article:14514738pubmed:abstractTextAlport syndrome (AS) is a type IV collagen hereditary disease characterized by progressive hematuric nephritis, hearing loss, and ocular changes. Mutations in the COL4A5 collagen gene are responsible for the more common X-linked dominant form of the disease characterized by much less severe disease in girls and women. A "European Community Alport Syndrome Concerted Action" (ECASCA) group was established to delineate the Alport syndrome phenotype in each gender and to determine genotype-phenotype correlations in a large number of families. Data concerning 329 families, 250 of them with an X-linked transmission, were collected. Characteristics of heterozygous girls and women belonging to the 195 families with proven COL4A5 mutation are compared with those of hemizygous boys and men. Hematuria was observed in 95% of carriers and consistently absent in the others. Proteinuria, hearing loss, and ocular defects developed in 75%, 28%, and 15%, respectively. The probability of developing end-stage renal disease or deafness before the age of 40 yr was 12% and 10%, respectively, in girls and women versus 90 and 80%, respectively, in boys and men. The risk of progression to end-stage renal disease appears to increase after the age of 60 yr in women. Because of the absence of genotype-phenotype correlation and the large intrafamilial phenotypic heterogeneity, early prognosis of the disease in X-linked Alport syndrome carriers remains moot. Risk factors for developing renal failure have been identified: the occurrence and progressive increase in proteinuria, and the development of a hearing defect.lld:pubmed
pubmed-article:14514738pubmed:languageenglld:pubmed
pubmed-article:14514738pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14514738pubmed:citationSubsetIMlld:pubmed
pubmed-article:14514738pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14514738pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14514738pubmed:statusMEDLINElld:pubmed
pubmed-article:14514738pubmed:monthOctlld:pubmed
pubmed-article:14514738pubmed:issn1046-6673lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:KissTs LTsLlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:KnebelmannBer...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:AntignacCorin...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:PirsonYvesYlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:TryggvasonKar...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:HertzJens...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:RenieriAlessa...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:DahanKarinKlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:GublerMarie...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:PerssonUlfUlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:MartinPaulaPlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:SanakMarekMlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:GrossOliverOlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:NetzerKai-Ola...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:WeberManfredMlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:RizzoniGianfr...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:SmeetsHubertHlld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:FlinterFrance...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:WieslanderJör...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:JaisJean...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:GiatrasIannis...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:SchröderCorne...lld:pubmed
pubmed-article:14514738pubmed:authorpubmed-author:CarvalhoMaria...lld:pubmed
pubmed-article:14514738pubmed:issnTypePrintlld:pubmed
pubmed-article:14514738pubmed:volume14lld:pubmed
pubmed-article:14514738pubmed:ownerNLMlld:pubmed
pubmed-article:14514738pubmed:authorsCompleteYlld:pubmed
pubmed-article:14514738pubmed:pagination2603-10lld:pubmed
pubmed-article:14514738pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:meshHeadingpubmed-meshheading:14514738...lld:pubmed
pubmed-article:14514738pubmed:year2003lld:pubmed
pubmed-article:14514738pubmed:articleTitleX-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.lld:pubmed
pubmed-article:14514738pubmed:affiliationBiostatistique et Informatique Médicale, Hôpital Necker Enfants Malades, Université René Descartes, Paris, France.lld:pubmed
pubmed-article:14514738pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14514738pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:1287entrezgene:pubmedpubmed-article:14514738lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:14514738lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14514738lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14514738lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14514738lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14514738lld:pubmed